Revenue Breakdown
Composition ()
No data
Revenue Streams
Perrigo Company PLC (PRGO) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Upper respiratory, accounting for 17.4% of total sales, equivalent to $182.00M. Other significant revenue streams include Pain and sleep-aids and Skincare and personal hygiene. Understanding this composition is critical for investors evaluating how PRGO navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Perrigo Company PLC maintains a gross margin of 32.64%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 7.61%, while the net margin is -127.49%. These profitability ratios, combined with a Return on Equity (ROE) of -38.66%, provide a clear picture of how effectively PRGO converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, PRGO competes directly with industry leaders such as VCEL and GLTO. With a market capitalization of $1.70B, it holds a significant position in the sector. When comparing efficiency, PRGO's gross margin of 32.64% stands against VCEL's 78.70% and GLTO's N/A. Such benchmarking helps identify whether Perrigo Company PLC is trading at a premium or discount relative to its financial performance.
